Pfizer Inc.
SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS

Last updated:

Abstract:

The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.

Status:
Application
Type:

Utility

Filling date:

20 Feb 2020

Issue date:

14 Jan 2021